Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP001222

Drug Information
NameTemsirolimus    
SynonymsDB06287; WAY-130,779; Torisel; CCI-779; MolPort-003-850-408; Cci 779; 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin; Torisel (TN); Temsirolimus; D06068; Temsirolimus [USAN]; WAY-CCI 779; NCGC00167518-01; Rapamycin 42-[3-hydroxy-2(hydroxymethyl)-2-methylpropanoate]; Temserolimus; CHEMBL1201182; Temsirolimus (JAN/USAN/INN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; NSC683864; Torisel, CCI-779, Temsirolimus; NSC-683864; S1044_Selleck; 343261-52-9; LS-186555; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone 4'-(2,2-bis(hydroxymethyl)propionate); Rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate); LS-187004; LS-187783; C15182; 162635-04-3; (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate; Rapamycin 42-(2,2-bis(hydroxymethyl)propionate)    
Trade NameTorisel    
CompanyWyeth    
IndicationRenal cell carcinomaApproved    [1]
Renal cell carcinomaPhase III    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntineoplastic Agents    
CAS NumberCAS 162635-04-3
FormularC56H87NO16    
PubChem Compound IDCID 23724530.    
PubChem Substance IDSID 17396179.    
TargetSerine/threonine-protein kinase mTORInhibitor[2]
Ref 1Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. To Reference
Ref 2Targeted therapies and their indications in solid neoplasias. Rev Med Interne. 2009 May;30(5):416-24. Epub 2009 Mar 18. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543